** Shares of drug developer Soleno Therapeutics SLNO.O fall ~6% to $54 premarket
** Co says U.S. FDA has extended review of its experimental drug to treat Prader–Willi syndrome, a rare genetic disorder
** The condition causes affected individuals to develop extreme hunger, which leads to chronic overeating, or hyperphagia, and obesity
** FDA determined that co's responses to recent information requests constituted major amendment to marketing application for the drug, diazoxide choline extended-release tablets
** The health regulator will now give its decision by March 27, 2025, compared with its previous action date of Dec. 27 this year
** FDA did not cite any safety, efficacy or manufacturing concerns, SLNO says
** Up to last close, stock up ~42% YTD
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.